fluconazole has been researched along with ibuprofen in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 13 (35.14) | 29.6817 |
| 2010's | 21 (56.76) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Akhtar, M; Alam, MM; Hasan, SM; Husain, A; Khanna, S; Zaman, MS | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fatahala, SS; Kamel, R; Mohamed, MS | 2 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Guo, M; Li, C; Li, YR; Liu, JC; Piao, HR; Sun, LP; Zhang, TY; Zheng, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chi, KQ; Liu, HY; Piao, HR; Sun, LP; Wei, ZY; Yu, ZK; Zheng, CJ | 1 |
| Basu, P; Elias, R; Fridman, M | 1 |
| Han, J; Liu, M; Liu, W; Liu, Y; Sun, B; Wang, Q; Yu, S | 1 |
| McCrory, RM; Scott, EM; Tariq, VN | 1 |
| Fonseca, AF; Mårdh, PA; Martinez-DE-Oliveira, J; Pina-Vaz, C; Rodrigues, AG; Sansonetty, F | 1 |
| Arai, R; Nishikawa, A; Sugita, T | 1 |
| Costa-de-Oliveira, S; Mårdh, PA; Pina-Vaz, C; Ricardo, E; Rodrigues, AG | 1 |
| Hynninen, VV; Laine, K; Leino, K; Lundgren, S; Neuvonen, PJ; Olkkola, KT; Rane, A; Valtonen, M; Vyyryläinen, H | 1 |
| Costa-de-Oliveira, S; Dias, AS; Guerra, J; Pina-Vaz, C; Ricardo, E; Rodrigues, AG | 1 |
| Fukazawa, H; Inoue, M; Kaneko, Y; Miyazaki, Y; Niki, M; Ohno, H; Tanabe, K; Umeyama, T; Urai, M | 1 |
| Costa-de-Oliveira, S; Miranda, IM; Pina-Vaz, C; Rodrigues, AG; Silva, AP; Silva-Dias, A | 1 |
| Ogundeji, AO; Pohl, CH; Sebolai, OM | 1 |
| Almashanu, S; Bier Palmon, R; Eventov-Friedman, S; Flidel-Rimon, O; Golan, A; Kats, N; Keidar, R; Marom, R; Troitzky, M; Zung, A | 1 |
| Bartoszewicz, M; Król, J; Nawrot, U | 1 |
2 review(s) available for fluconazole and ibuprofen
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluconazole and ibuprofen
| Article | Year |
|---|---|
Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
Topics: Adult; Analgesics, Non-Narcotic; Antifungal Agents; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fluconazole; Half-Life; Humans; Ibuprofen; Male; Pyrimidines; Therapeutic Equivalency; Triazoles; Voriconazole | 2006 |
34 other study(ies) available for fluconazole and ibuprofen
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synthesis of 6-aminomethyl derivatives of benzopyran-4-one with dual biological properties: anti-inflammatory-analgesic and antimicrobial.
Topics: Amination; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Benzopyrans; Flavones; Fungi; Lipid Peroxidation; Methylation; Microbial Sensitivity Tests; Molecular Structure | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Synthesis and biological evaluation of some thio containing pyrrolo [2,3-d]pyrimidine derivatives for their anti-inflammatory and anti-microbial activities.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Fungi; Male; Microbial Sensitivity Tests; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfur | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
New condensed pyrroles of potential biological interest syntheses and structure-activity relationship studies.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacillus subtilis; Carrageenan; Edema; Hindlimb; Ibuprofen; Male; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Staphylococcus aureus; Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Drug Resistance, Multiple, Bacterial; Furans; Gram-Negative Bacteria; Gram-Positive Cocci; Ibuprofen; Indomethacin; Mice; Pyrazoles | 2015 |
Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Cell Line; Cell Proliferation; Chalcone; Dose-Response Relationship, Drug; Guanidines; Humans; Hydrazones; Microbial Sensitivity Tests; Molecular Structure; Salmonella typhimurium; Structure-Activity Relationship | 2016 |
Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles.
Topics: Antifungal Agents; Candida; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P450 Family 51; Ergosterol; Fluconazole; Microbial Sensitivity Tests; Stereoisomerism | 2022 |
Novel Aryl Alkamidazole Derivatives as Multifunctional Antifungal Inhibitors: Design, Synthesis, and Biological Evaluation.
Topics: Antifungal Agents; Drug Design; Microbial Sensitivity Tests; Structure-Activity Relationship | 2022 |
Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Densitometry; Drug Synergism; Fluconazole; Humans; Ibuprofen; Microbial Sensitivity Tests; Parabens; Sodium Salicylate | 1995 |
Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species.
Topics: Antifungal Agents; Candida; Cell Membrane Permeability; Drug Synergism; Fluconazole; Ibuprofen; Species Specificity | 2000 |
Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Drug Resistance, Fungal; Drug Synergism; Fluconazole; Humans; Ibuprofen; Microbial Sensitivity Tests | 2005 |
Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
Topics: Antifungal Agents; Candida; Drug Resistance, Fungal; Drug Synergism; Flow Cytometry; Fluconazole; Fungal Proteins; Ibuprofen; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Staining and Labeling; Triazoles; Voriconazole | 2005 |
Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
Topics: Antifungal Agents; Azoles; Candida albicans; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Enzyme Inhibitors; Fluconazole; Fungal Proteins; Gene Expression Profiling; Humans; Ibuprofen; Membrane Transport Proteins; Microbial Sensitivity Tests; Tacrolimus | 2009 |
Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida albicans; Candidiasis; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Fluconazole; Fungal Proteins; Gene Expression; Ibuprofen; Membrane Transport Proteins; Microbial Sensitivity Tests; Omeprazole; Phenylpropionates; Proton Pump Inhibitors | 2014 |
Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Female; Fluconazole; Fungal Proteins; Ibuprofen; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests | 2015 |
Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspirin; Cell Death; Cell Line; Cryptococcosis; Cryptococcus; Drug Repositioning; Drug Resistance, Fungal; Fluconazole; Ibuprofen; Mice; RAW 264.7 Cells | 2016 |
Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Cefotaxime; Cesarean Section; Diuretics; Dopamine; Ductus Arteriosus, Patent; Erythrocyte Transfusion; Female; Fluconazole; Furosemide; Humans; Hypoglycemic Agents; Hypothyroidism; Ibuprofen; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Insulin; Intensive Care Units, Neonatal; Male; Multivariate Analysis; Neonatal Screening; Pneumothorax; Respiration, Artificial; Retrospective Studies; Risk Factors; Sympathomimetics; Thyrotropin; Time Factors; Vancomycin | 2017 |
Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
Topics: Acetaminophen; Analgesics; Antifungal Agents; Aspirin; Candida; Candida albicans; Candida glabrata; Candidiasis; Dipyrone; Drug Resistance, Fungal; Fluconazole; Humans; Ibuprofen; Itraconazole; Meloxicam; Microbial Sensitivity Tests; Nitriles; Pyridines; Triazoles; Voriconazole | 2018 |